| 1 |
Miceli G, Calvaruso V, Casuccio A, Pennisi G, Licata M, Pintus C, Basso MG, Velardo M, Daidone M, Amodio E, Petta S, Simone F, Cabibbo G, Di Raimondo D, Craxì A, Pinto A, Tuttolomondo A. Heart rate variability is associated with disease severity and portal hypertension in cirrhosis. Hepatol Commun 2023;7:e0050. [PMID: 36757394 DOI: 10.1097/HC9.0000000000000050] [Reference Citation Analysis]
|
| 2 |
Queck A, Schwierz L, Gu W, Ferstl PG, Jansen C, Uschner FE, Praktiknjo M, Chang J, Brol MJ, Schepis F, Merli M, Strassburg CP, Lehmann J, Meyer C, Trebicka J. Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS. Hepatology 2023;77:466-75. [PMID: 35869810 DOI: 10.1002/hep.32676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 3 |
Liu Y, Ran L, Zhang H, Ren H, Jiang X, Liao P, Ou M. Comparison of Child-Pugh, MELD, MELD-Na, and ALBI Scores in Predicting In-Hospital Mortality in Patients with HCC. IJCM 2023;14:148-162. [DOI: 10.4236/ijcm.2023.143011] [Reference Citation Analysis]
|
| 4 |
Kang SH, Baik SK. Peripheral vasculature in portal hypertension. Cardio-Hepatology 2023. [DOI: 10.1016/b978-0-12-817394-7.00012-7] [Reference Citation Analysis]
|
| 5 |
Mahfoz AM, Gawish AY. Insight into the hepatoprotective, hypolipidemic, and antidiabetic impacts of aliskiren in streptozotocin-induced diabetic liver disease in mice. Diabetol Metab Syndr 2022;14:163. [PMID: 36316746 DOI: 10.1186/s13098-022-00935-5] [Reference Citation Analysis]
|
| 6 |
Wang C, Huang X, Lan X, Lan D, Huang Z, Ye S, Ran Y, Bi X, Zhou J, Che X. Research progress of spontaneous ruptured hepatocellular carcinoma: Systematic review and meta-analysis. Front Oncol 2022;12:973857. [DOI: 10.3389/fonc.2022.973857] [Reference Citation Analysis]
|
| 7 |
Jeong J, Tanaka M, Iwakiri Y. Hepatic lymphatic vascular system in health and disease. J Hepatol 2022;77:206-18. [PMID: 35157960 DOI: 10.1016/j.jhep.2022.01.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 8 |
Efimov DY, Fedoruk DA, Nosik AV, Kirkovsky LV, Kozak ON, Avdey EL, Savchenko AV, Korotkov SV, Shcherba AE, Rummo OO. Evolution of approaches to portal hypertension syndrome and principles underlying treatment personalization. Ann hir gepatol 2022;27:39-47. [DOI: 10.16931/1995-5464.2022-2-39-47] [Reference Citation Analysis]
|
| 9 |
Liu S, Meng Q, Xu Y, Zhou J. Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion. Gastroenterol Rep (Oxf) 2021;9:505-20. [PMID: 34925848 DOI: 10.1093/gastro/goab040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 10 |
Elkrief L, Buyse S, Panhard X, Baudry C, Gault N, Moreau R, Rautou PE, Belghiti J, Durand F, Bedossa P, Paradis V, Valla D. Microcirculatory changes in the liver of patients with refractory ascites and their relationship with diabetes and alcohol. Eur J Gastroenterol Hepatol 2021;33:e145-52. [PMID: 33208687 DOI: 10.1097/MEG.0000000000001990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Morelli MC, Rendina M, La Manna G, Alessandria C, Pasulo L, Lenci I, Bhoori S, Messa P, Biancone L, Gesualdo L, Russo FP, Petta S, Burra P; Italian Association for the Study of Liver, and the Italian Society of Nephrology. Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). Dig Liver Dis 2021;53 Suppl 2:S49-86. [PMID: 34074490 DOI: 10.1016/j.dld.2021.03.035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 12 |
Lee BT, Yang AH, Urban S, Kim KY, Ter-Oganesyan R, Yuan L, Han HH, Khemichian S, Kahn JA, Kim B. Applying the original model for end-stage liver disease score rather than the model for end-stage liver disease-Na score for risk stratification prior to transjugular intrahepatic portosystemic shunt procedures. Eur J Gastroenterol Hepatol 2021;33:541-6. [PMID: 32398491 DOI: 10.1097/MEG.0000000000001760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
de Oliveira Gomes CG, de Andrade MVM, Guedes LR, Rocha HC, Guimarães RG, Carvalho FAC, Vilela EG. Evaluation of the Biomarkers HMGB1 and IL-6 as Predictors of Mortality in Cirrhotic Patients with Acute Kidney Injury. Mediators Inflamm 2020;2020:2867241. [PMID: 33061824 DOI: 10.1155/2020/2867241] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 14 |
Donati G, Angeletti A, Gasperoni L, Piscaglia F, Croci Chiocchini AL, Scrivo A, Natali T, Ullo I, Guglielmo C, Simoni P, Mancini R, Bolondi L, La Manna G. Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study). J Nephrol 2021;34:77-88. [PMID: 32710265 DOI: 10.1007/s40620-020-00799-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 15 |
Atsukawa M, Tsubota A, Takaguchi K, Toyoda H, Iwasa M, Ikegami T, Chuma M, Nozaki A, Uojima H, Hiraoka A, Fukunishi S, Yokohama K, Tada T, Kato K, Abe H, Tani J, Okubo H, Watanabe T, Hattori N, Tsutsui A, Senoh T, Yoshida Y, Okubo T, Itokawa N, Nakagawa-Iwashita A, Kondo C, Arai T, Michitaka K, Iio E, Kumada T, Tanaka Y, Takei Y, Iwakiri K. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. J Gastroenterol Hepatol 2020;35:1229-37. [PMID: 31881554 DOI: 10.1111/jgh.14965] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 16 |
Tripathy A, Maiti R, Jena M, Mishra A, Srinivasan A. Effect of alpha agonists on the prevention of postparacentesis circulatory dysfunction in patients with refractory or recurrent ascites: a meta-analysis. Eur J Gastroenterol Hepatol 2020;32:303-11. [PMID: 31688312 DOI: 10.1097/MEG.0000000000001594] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 17 |
Sakaida I, Terai S, Kurosaki M, Okada M, Hirano T, Fukuta Y. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study). J Gastroenterol 2020;55:800-10. [PMID: 32388692 DOI: 10.1007/s00535-020-01691-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 18 |
Bai Z, An Y, Guo X, Teschke R, Méndez-Sánchez N, Li H, Qi X. Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence. Can J Gastroenterol Hepatol 2020;2020:5106958. [PMID: 32676484 DOI: 10.1155/2020/5106958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 19 |
Arase Y, Kagawa T, Tsuruya K, Sato H, Teramura E, Anzai K, Hirose S, Deguchi R, Shiraishi K, Mine T. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites. Clin Drug Investig 2019;39:45-54. [PMID: 30284699 DOI: 10.1007/s40261-018-0714-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Ferrusquía-acosta J, Hernández-gea V. TIPS Indications and Contraindications—Pushing the Limits: Is Earlier Better? Curr Hepatology Rep 2019;18:87-95. [DOI: 10.1007/s11901-019-00453-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 21 |
Wan YM, Li YH, Xu ZY, Wu HM, Wu XN, Xu Y, Guo T. Transjugular Intrahepatic Portosystemic Shunt:The Impact of Portal Venous Pressure Declines on Shunt Patency and Clinical Efficacy. Acad Radiol 2019;26:188-95. [PMID: 29934023 DOI: 10.1016/j.acra.2018.05.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 22 |
Deep A, Saxena R, Jose B. Acute kidney injury in children with chronic liver disease. Pediatr Nephrol 2019;34:45-59. [PMID: 29497824 DOI: 10.1007/s00467-018-3893-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 23 |
Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications. Clin Mol Hepatol 2018;24:230-77. [PMID: 29991196 DOI: 10.3350/cmh.2018.1005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 24 |
Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int 2018;38:570-80. [PMID: 28921803 DOI: 10.1111/liv.13589] [Cited by in Crossref: 95] [Cited by in F6Publishing: 98] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 25 |
Santoro A, Mancini E. The Kidney in Hepatorenal Syndrome (I Part). Int J Artif Organs 2004;27:95-103. [DOI: 10.1177/039139880402700204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 26 |
Deep A, Saxena R. Acute Kidney Injury in Liver Disease. Critical Care Nephrology and Renal Replacement Therapy in Children 2018. [DOI: 10.1007/978-3-319-90281-4_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 27 |
Seo YS. 2017 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines for Ascites and Related Complications: What Has Been Changed from the 2011 KASL Clinical Practice Guidelines? Korean J Gastroenterol 2018;72:179. [DOI: 10.4166/kjg.2018.72.4.179] [Reference Citation Analysis]
|
| 28 |
Uojima H, Hidaka H, Nakayama T, Sung JH, Ichita C, Tokoro S, Masuda S, Sasaki A, Koizumi K, Egashira H, Kako M. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study. World J Gastroenterol 2017; 23(45): 8062-8072 [PMID: 29259382 DOI: 10.3748/wjg.v23.i45.8062] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 29 |
Zhao R, Lu J, Shi Y, Zhao H, Xu K, Sheng J. Current management of refractory ascites in patients with cirrhosis. J Int Med Res 2018;46:1138-45. [PMID: 29210304 DOI: 10.1177/0300060517735231] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 30 |
Amer MO, Elsiesy H. Ascites: Causes, Diagnosis, and Treatment. Liver Cirrhosis - Update and Current Challenges 2017. [DOI: 10.5772/intechopen.68868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 31 |
Tsochatzis EA, Gerbes AL. Diagnosis and treatment of ascites. J Hepatol 2017;67:184-5. [PMID: 28119010 DOI: 10.1016/j.jhep.2017.01.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 32 |
Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, Mathurin P, Otal P, Cabarrou P, Péron JM, Vinel JP. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology 2017;152:157-63. [PMID: 27663604 DOI: 10.1053/j.gastro.2016.09.016] [Cited by in Crossref: 233] [Cited by in F6Publishing: 241] [Article Influence: 38.8] [Reference Citation Analysis]
|
| 33 |
Cheng XS, Tan JC, Kim WR. Management of renal failure in end-stage liver disease: A critical appraisal. Liver Transpl 2016;22:1710-9. [PMID: 27875032 DOI: 10.1002/lt.24609] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 34 |
Iwamoto T, Maeda M, Hisanaga T, Saeki I, Fujisawa K, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis. Intern Med 2016;55:2911-6. [PMID: 27746425 DOI: 10.2169/internalmedicine.55.6819] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 35 |
Wang P, Huang G, Tam N, Wu C, Fu S, Hughes BP, Wu L, He X. Influence of preoperative sodium concentration on outcome of patients with hepatitis B virus cirrhosis after liver transplantation. Eur J Gastroenterol Hepatol 2016;28:1210-5. [PMID: 27362549 DOI: 10.1097/MEG.0000000000000690] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 36 |
Tanaka M, Iwakiri Y. The Hepatic Lymphatic Vascular System: Structure, Function, Markers, and Lymphangiogenesis. Cell Mol Gastroenterol Hepatol 2016;2:733-49. [PMID: 28105461 DOI: 10.1016/j.jcmgh.2016.09.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 37 |
Merli M, Lucidi C, Di Gregorio V, Lattanzi B, Giannelli V, Giusto M, Farcomeni A, Ceccarelli G, Falcone M, Riggio O, Venditti M. An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial. Hepatology 2016;63:1632-9. [PMID: 26529126 DOI: 10.1002/hep.28332] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 38 |
Zhang Q, Guo X, Zhao S, Pang X, Wang Y, Zhang Y, Chi B. Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients. Exp Ther Med 2016;11:1348-54. [PMID: 27073448 DOI: 10.3892/etm.2016.3037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 39 |
Baraldi O, Valentini C, Donati G, Comai G, Cuna V, Capelli I, Angelini ML, Moretti MI, Angeletti A, Piscaglia F, Manna GL. Hepatorenal syndrome: Update on diagnosis and treatment. World J Nephrol 2015; 4(5): 511-520 [PMID: 26558188 DOI: 10.5527/wjn.v4.i5.511] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 40 |
Møller S, Bendtsen F. Cirrhotic Multiorgan Syndrome. Dig Dis Sci 2015;60:3209-25. [PMID: 26112989 DOI: 10.1007/s10620-015-3752-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 41 |
Saxena V, Lai JC. Kidney Failure and Liver Allocation: Current Practices and Potential Improvements. Adv Chronic Kidney Dis 2015;22:391-8. [PMID: 26311601 DOI: 10.1053/j.ackd.2015.05.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 42 |
Kim HY, Jang JW. Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score. World J Gastroenterol 2015; 21(25): 7637-7647 [PMID: 26167066 DOI: 10.3748/wjg.v21.i25.7637] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 75] [Article Influence: 9.1] [Reference Citation Analysis]
|
| 43 |
Møller S, Bendtsen F. Complications of cirrhosis. A 50 years flashback. Scand J Gastroenterol 2015;50:763-80. [PMID: 25881709 DOI: 10.3109/00365521.2015.1021709] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 44 |
Urrunaga NH, Mindikoglu AL, Rockey DC. Renal dysfunction in cirrhosis. Curr Opin Gastroenterol 2015;31:215-23. [PMID: 25763790 DOI: 10.1097/MOG.0000000000000168] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 45 |
Wiese S, Bendtsen F, Møller S. Cardiac Biomarkers in Cirrhosis and Portal Hypertension: Relation to Circulatory and Cardiac Dysfunction. Biomarkers in Cardiovascular Disease 2015. [DOI: 10.1007/978-94-007-7741-5_19-1] [Reference Citation Analysis]
|
| 46 |
Pathil-warth A, Stremmel W, Berg T, Benckert J, Wiegand J, Pfersdorff M, Kraus M, Banasch M, Schmidt WE, Wasmuth H, Trautwein C. Entzündliche Lebererkrankungen. Viszeralmedizin 2015. [DOI: 10.1007/978-3-642-14301-4_23] [Reference Citation Analysis]
|
| 47 |
Møller S, Henriksen JH, Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects. World J Gastroenterol 2014; 20(42): 15499-15517 [PMID: 25400435 DOI: 10.3748/wjg.v20.i42.15499] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 48 |
Chan AC, Fan ST. Criteria for liver transplantation in ACLF and outcome. Hepatol Int. 2015;9:355-359. [PMID: 25788183 DOI: 10.1007/s12072-014-9585-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 49 |
Yee J. Kidney failure: cardiorenal and venorenal. Adv Chronic Kidney Dis 2014;21:453-5. [PMID: 25443569 DOI: 10.1053/j.ackd.2014.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 50 |
Teneva B, Karaslavova E. Prognostic value of serum cystatin C levels in cirrhotic patients with normal serum creatinine. Open Medicine 2014;9:625-31. [DOI: 10.2478/s11536-013-0287-x] [Reference Citation Analysis]
|
| 51 |
Pugliese R, Fonseca EA, Porta G, Danesi V, Guimaraes T, Porta A, Miura IK, Borges C, Candido H, Benavides M, Feier FH, Godoy A, Cardoso RA, Kondo M, Chapchap P, Neto JS. Ascites and serum sodium are markers of increased waiting list mortality in children with chronic liver failure. Hepatology 2014;59:1964-71. [PMID: 24122953 DOI: 10.1002/hep.26776] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 52 |
Gomez EV, Gonzalez AT, Bertot LC, Yasells Garcia A, Rodriguez YS, Perez YM. Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosis. PLoS One 2014;9:e95736. [PMID: 24755710 DOI: 10.1371/journal.pone.0095736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 53 |
Leithead JA, Hayes PC, Ferguson JW. Review article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction. Aliment Pharmacol Ther 2014;39:699-711. [PMID: 24528130 DOI: 10.1111/apt.12653] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 54 |
Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: An updated meta-analysis. World J Gastroenterol 2014; 20(10): 2704-2714 [PMID: 24627607 DOI: 10.3748/wjg.v20.i10.2704] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 91] [Article Influence: 9.4] [Reference Citation Analysis]
|
| 55 |
Mavija Z, Mavija M. Comparison of abdominal puncture and diuretics during ascites treatment. Scripta Medica 2014;45:51-55. [DOI: 10.5937/scrimed1402051m] [Reference Citation Analysis]
|
| 56 |
Licata A, Maida M, Bonaccorso A, Macaluso FS, Cappello M, Craxì A, Almasio PL. Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. World J Hepatol 2013;5:685-91. [PMID: 24432185 DOI: 10.4254/wjh.v5.i12.685] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 57 |
Gipson A. The pathophysiology of hepatorenal syndrome. Gastrointestinal Nursing 2013;11:29-35. [DOI: 10.12968/gasn.2013.11.7.29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 58 |
Kim HJ, Lee HW. Important predictor of mortality in patients with end-stage liver disease. Clin Mol Hepatol. 2013;19:105-115. [PMID: 23837134 DOI: 10.3350/cmh.2013.19.2.105] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 59 |
Henriksen JH, Møller S. Ascites. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 2013;5:1-116. [DOI: 10.4199/c00085ed1v01y201305isp039] [Reference Citation Analysis]
|
| 60 |
Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H; Vienna Hepatic Hemodynamic Lab. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol 2013;58:911-21. [PMID: 23262249 DOI: 10.1016/j.jhep.2012.12.011] [Cited by in Crossref: 223] [Cited by in F6Publishing: 232] [Article Influence: 22.3] [Reference Citation Analysis]
|
| 61 |
Lau T, Ahmad J. Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. Hepat Med. 2013;5:1-10. [PMID: 24696621 DOI: 10.2147/hmer.s9049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 62 |
Wong DKH. Management of Ascites. Hepatology: Diagnosis and Clinical Management 2012. [DOI: 10.1002/9781118314968.ch6] [Reference Citation Analysis]
|
| 63 |
Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Loong CC, Chiou YY, Huo TI. Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. Dig Liver Dis 2012;44:868-74. [PMID: 22647396 DOI: 10.1016/j.dld.2012.04.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 64 |
Højmark Hansen M, Kristensen SS, Schaffalitzky de Muckadell OB, Thiesson HC, Andrew R, Dam Fialla A. The role of glucocorticoids in sodium retention in cirrhotic patients: a double blind, randomized, crossover study. Scand J Gastroenterol 2012;47:1030-6. [PMID: 22670598 DOI: 10.3109/00365521.2012.690044] [Reference Citation Analysis]
|
| 65 |
Hartleb M, Gutkowski K. Kidneys in chronic liver diseases. World J Gastroenterol 2012; 18(24): 3035-3049 [PMID: 22791939 DOI: 10.3748/wjg.v18.i24.3035] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 66 |
Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, Sarrazin C, Hoste E, Van Vlierberghe H, Escorsell A, Hafer C, Schreiner O, Galle PR, Mancini E, Caraceni P, Karvellas CJ, Salmhofer H, Knotek M, Ginès P, Kozik-Jaromin J, Rifai K; HELIOS Study Group. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012;142:782-789.e3. [PMID: 22248661 DOI: 10.1053/j.gastro.2011.12.056] [Cited by in Crossref: 276] [Cited by in F6Publishing: 285] [Article Influence: 25.1] [Reference Citation Analysis]
|
| 67 |
Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 101] [Cited by in F6Publishing: 105] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 68 |
Kim DJ, Kang HS, Choi HS, Cho HJ, Kim ES, Keum B, An H, Kim JH, Seo YS, Kim YS. Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels. Korean J Hepatol. 2011;17:130-138. [PMID: 21757984 DOI: 10.3350/kjhep.2011.17.2.130] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 69 |
Arroyo V, Fernández J. Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 2011;7:517-26. [DOI: 10.1038/nrneph.2011.96] [Cited by in Crossref: 40] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 70 |
Nasr G, Hassan A, Ahmed S, Serwah A. Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites. J Cardiovasc Dis Res 2010;1:136-44. [PMID: 21187868 DOI: 10.4103/0975-3583.70914] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 71 |
Kim MY, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol 2010;16:347-52. [PMID: 21415576 DOI: 10.3350/kjhep.2010.16.4.347] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 72 |
Sharawey MA, Shawky EM, Ali LH, Mohammed AA, Hassan HA, Fouad YM. Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis. Hepatol Int. 2011;5:927-933. [PMID: 21484118 DOI: 10.1007/s12072-011-9266-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 73 |
López AG. Hidrocele bilateral en paciente con cirrosis hepática. FMC - Formación Médica Continuada en Atención Primaria 2011;18:43. [DOI: 10.1016/s1134-2072(11)70015-9] [Reference Citation Analysis]
|
| 74 |
Kelbel C, Voigtländer T. Drainagen und Punktionen. Internistische Intensivmedizin und Notfallmedizin 2011. [DOI: 10.1007/978-3-642-16970-0_8] [Reference Citation Analysis]
|
| 75 |
Henriksen JH. Regulation of the Extracellular Fluid Volume and Renal Function. Chronic Liver Failure 2011. [DOI: 10.1007/978-1-60761-866-9_12] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 76 |
Kalambokis GN, Pappas K, Baltayiannis G, Katsanou A, Tsianos EV. Effects of terlipressin on water excretion after oral water load test in nonazotemic cirrhotic patients with ascites without hyponatremia. Scand J Gastroenterol 2010;45:1509-15. [PMID: 20695722 DOI: 10.3109/00365521.2010.510576] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 77 |
Magan AA, Khalil AA, Ahmed MH. Terlipressin and hepatorenal syndrome: What is important for nephrologists and hepatologists. World J Gastroenterol 2010; 16(41): 5139-5147 [PMID: 21049548 DOI: 10.3748/wjg.v16.i41.5139] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 78 |
Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI, Lee SD. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 2010;53:108-17. [PMID: 20451283 DOI: 10.1016/j.jhep.2010.01.038] [Cited by in Crossref: 128] [Cited by in F6Publishing: 135] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 79 |
Yang YW, Wu CH, Hu RH, Ho MC, Tsai MK, Wu YM, Lee PH. Longitudinal assessment of prognostic factors for patients with hepatorenal syndrome in a tertiary center. Hepatol Int. 2010;4:507-510. [PMID: 20827408 DOI: 10.1007/s12072-010-9180-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 80 |
Fukuhara T, Ikegami T, Morita K, Umeda K, Ueda S, Nagata S, Sugimachi K, Gion T, Yoshizumi T, Soejima Y, Taketomi A, Maehara Y. Impact of preoperative serum sodium concentration in living donor liver transplantation. J Gastroenterol Hepatol 2010;25:978-84. [PMID: 20546453 DOI: 10.1111/j.1440-1746.2009.06162.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 81 |
Møller S, Henriksen JH, Bendtsen F. Ascites: pathogenesis and therapeutic principles. Scand J Gastroenterol 2009;44:902-11. [PMID: 19479632 DOI: 10.1080/00365520902912555] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 82 |
Hsu CY, Lin HC, Huang YH, Su CW, Lee FY, Huo TI, Lee PC, Lee JY, Lee SD. Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. Dig Liver Dis 2010;42:137-42. [PMID: 19595648 DOI: 10.1016/j.dld.2009.06.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 83 |
Hasper D, Berg T. Hepatorenal Syndrome. Management of Acute Kidney Problems 2010. [DOI: 10.1007/978-3-540-69441-0_31] [Reference Citation Analysis]
|
| 84 |
Kowdley KV. Ascites. Netter's Gastroenterology 2010. [DOI: 10.1016/b978-1-4377-0121-0.50230-0] [Reference Citation Analysis]
|
| 85 |
Kowdley KV. Hepatorenal Syndrome. Netter's Gastroenterology 2010. [DOI: 10.1016/b978-1-4377-0121-0.50232-4] [Reference Citation Analysis]
|
| 86 |
Lee JW. Renal dysfunction in patients with chronic liver disease. Electrolyte Blood Press 2009;7:42-50. [PMID: 21468185 DOI: 10.5049/EBP.2009.7.2.42] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 87 |
Seo YS, Jung ES, An H, Kim JH, Jung YK, Kim JH, Yim HJ, Yeon JE, Byun KS, Kim CD, Ryu HS, Um SH. Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver Int 2009;29:1521-7. [PMID: 19725889 DOI: 10.1111/j.1478-3231.2009.02105.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 88 |
Huang HC, Lee FY, Huo TI. Major adverse events, pretransplant assessment and outcome prediction. J Gastroenterol Hepatol 2009;24:1716-24. [PMID: 20136958 DOI: 10.1111/j.1440-1746.2009.06025.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 89 |
Gitto S, Lorenzini S, Biselli M, Conti F, Andreone P, Bernardi M. Allocation priority in non-urgent liver transplantation: An overview of proposed scoring systems. Dig Liver Dis 2009;41:700-6. [PMID: 19502118 DOI: 10.1016/j.dld.2009.04.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 90 |
Rochling FA, Zetterman RK. Management of Ascites: . Drugs 2009;69:1739-60. [DOI: 10.2165/11316390-000000000-00000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 91 |
Jacqmin S, Ghiglione S, Ozier Y. Le syndrome hépatorénal. Le Praticien en Anesthésie Réanimation 2009;13:262-272. [DOI: 10.1016/j.pratan.2009.07.004] [Reference Citation Analysis]
|
| 92 |
Lv XH, Liu HB, Wang Y, Wang BY, Song M, Sun MJ. Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis. J Gastroenterol Hepatol 2009;24:1547-53. [PMID: 19686416 DOI: 10.1111/j.1440-1746.2009.05913.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 93 |
Colmenero J, Castro-Narro G, Navasa M. [The value of MELD in the allocation of priority for liver transplantation candidates]. Gastroenterol Hepatol 2010;33:330-6. [PMID: 19631411 DOI: 10.1016/j.gastrohep.2009.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 94 |
Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009;49:2087-107. [PMID: 19475696 DOI: 10.1002/hep.22853] [Cited by in Crossref: 628] [Cited by in F6Publishing: 694] [Article Influence: 44.9] [Reference Citation Analysis]
|
| 95 |
Vilas-Boas WW, Ribeiro-Oliveira Jr A, Pereira RM, Ribeiro RDC, Almeida J, Nadu AP, Simões e Silva AC, Santos RASD. Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis. World J Gastroenterol 2009; 15(20): 2512-2519 [PMID: 19469002 DOI: 10.3748/wjg.15.2512] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 96 |
Kim JH, Kim JH, Choi JH, Kim CH, Jung YK, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Scand J Gastroenterol 2009;44:346-57. [PMID: 18991165 DOI: 10.1080/00365520802530838] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 97 |
Mancini E, Santoro A. Pathophysiology of the Hepatorenal Syndrome. Critical Care Nephrology 2009. [DOI: 10.1016/b978-1-4160-4252-5.50201-x] [Reference Citation Analysis]
|
| 98 |
Andrikos E, Balafa O. Pharmacological Treatment for Hepatorenal Syndrome. Critical Care Nephrology 2009. [DOI: 10.1016/b978-1-4160-4252-5.50204-5] [Reference Citation Analysis]
|
| 99 |
Navarro VJ, Rossi S, Herrine SK. HEPATIC CIRRHOSIS. Pharmacology and Therapeutics 2009. [DOI: 10.1016/b978-1-4160-3291-5.50038-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 100 |
Erkrankungen des Gastrointestinalsystems. Innere Medizin 2009. [DOI: 10.1016/b978-3-437-42831-9.10015-4] [Reference Citation Analysis]
|
| 101 |
Gentilini P, La Villa G. Liver-kidney pathophysiological interrelationships in liver diseases. Dig Liver Dis 2008;40:909-19. [PMID: 18621592 DOI: 10.1016/j.dld.2008.05.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 102 |
Huo TI, Lin HC, Hsia CY, Huang YH, Wu JC, Chiang JH, Chiou YY, Lui WY, Lee PC, Lee SD. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis 2008;40:882-9. [PMID: 18339595 DOI: 10.1016/j.dld.2008.01.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 103 |
Krag A, Borup T, Møller S, Bendtsen F. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther 2008;25:1105-40. [PMID: 19018483 DOI: 10.1007/s12325-008-0118-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 104 |
Moller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int. 2008;2:416-428. [PMID: 19669317 DOI: 10.1007/s12072-008-9100-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 105 |
Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, Therneau TM. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018-1026. [PMID: 18768945 DOI: 10.1056/nejmoa080120910.1053/jhep.2001.22172] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 106 |
Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, Therneau TM. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018-26. [PMID: 18768945 DOI: 10.1056/NEJMoa0801209] [Cited by in Crossref: 934] [Cited by in F6Publishing: 926] [Article Influence: 62.3] [Reference Citation Analysis]
|
| 107 |
Wang LN, Jiang HQ, Yang J, Wang YZ, Lv XP. Increased renal cell apoptosis and its mechanism in rats with biliary cirrhosis. Shijie Huaren Xiaohua Zazhi 2008; 16(24): 2702-2707 [DOI: 10.11569/wcjd.v16.i24.2702] [Reference Citation Analysis]
|
| 108 |
Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008;48 Suppl 1:S68-92. [PMID: 18304681 DOI: 10.1016/j.jhep.2008.01.021] [Cited by in Crossref: 204] [Cited by in F6Publishing: 208] [Article Influence: 13.6] [Reference Citation Analysis]
|
| 109 |
Singh V, Dheerendra PC, Singh B, Nain CK, Chawla D, Sharma N, Bhalla A, Mahi SK. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2008;103:1399-405. [PMID: 18547224 DOI: 10.1111/j.1572-0241.2008.01787.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 110 |
Gonzlez-alonso R, Crespo L, Garca-aguilera X, Albillos Martnez A. Ascitis y s?ndrome hepatorrenal en la cirrosis hep?tica. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2008;10:702-712. [DOI: 10.1016/s0211-3449(08)73140-0] [Reference Citation Analysis]
|
| 111 |
Opciones en el tratamiento de la ascitis. Nursing (Ed española) 2008;26:34. [DOI: 10.1016/s0212-5382(08)70676-9] [Reference Citation Analysis]
|
| 112 |
Pépin M, Ginès P. Management of Hepatorenal Syndrome. Therapy in Nephrology & Hypertension 2008. [DOI: 10.1016/b978-141605484-9.50007-1] [Reference Citation Analysis]
|
| 113 |
Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007;46:1863-71. [PMID: 18027874 DOI: 10.1002/hep.21901] [Cited by in Crossref: 109] [Cited by in F6Publishing: 111] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 114 |
Bosch J. Vascular deterioration in cirrhosis: the big picture. J Clin Gastroenterol 2007;41 Suppl 3:S247-53. [PMID: 17975472 DOI: 10.1097/MCG.0b013e3181572357] [Cited by in Crossref: 106] [Cited by in F6Publishing: 106] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 115 |
Jacqmin S, Ozier Y, Sogni P. Syndrome hépato-rénal. Le point sur …. [DOI: 10.1007/978-2-287-71152-7_11] [Reference Citation Analysis]
|
| 116 |
Biggins SW. Beyond the numbers: rational and ethical application of outcome models for organ allocation in liver transplantation. Liver Transpl 2007;13:1080-3. [PMID: 17663407 DOI: 10.1002/lt.21210] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 117 |
What are the options for managing ascites? Nursing 2007;37:64hn6. [DOI: 10.1097/01.nurse.0000261838.86112.3d] [Reference Citation Analysis]
|
| 118 |
Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol 2007;46:213-21. [PMID: 17156883 DOI: 10.1016/j.jhep.2006.09.012] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 119 |
Kelbel C. Aszitespunktion. Internistische Intensivmedizin und Notfallmedizin. [DOI: 10.1007/978-3-540-49662-5_9] [Reference Citation Analysis]
|
| 120 |
Cárdenas A, Arroyo V. Management of ascites and hepatic hydrothorax. Best Pract Res Clin Gastroenterol 2007;21:55-75. [PMID: 17223497 DOI: 10.1016/j.bpg.2006.07.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 121 |
Senzolo M, Cholongitas E, Tibballs J, Burroughs A, Patch D. Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome. Eur J Gastroenterol Hepatol 2006;18:1143-50. [PMID: 17033432 DOI: 10.1097/01.meg.0000236872.85903.3f] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 122 |
Libbrecht L, Cassiman D, Verslype C, Maleux G, Van Hees D, Pirenne J, Nevens F, Roskams T. Clinicopathological features of focal nodular hyperplasia-like nodules in 130 cirrhotic explant livers. Am J Gastroenterol 2006;101:2341-6. [PMID: 17032200 DOI: 10.1111/j.1572-0241.2006.00783.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 123 |
Debray D, Yousef N, Durand P. New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients. Paediatr Drugs 2006;8:1-13. [PMID: 16494508 DOI: 10.2165/00148581-200608010-00001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 124 |
Pariente A. Décompensation ascitique. Gastroentérologie Clinique et Biologique 2006;30:870-874. [DOI: 10.1016/s0399-8320(06)73334-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 125 |
Dib N, Oberti F, Calès P. Current management of the complications of portal hypertension: variceal bleeding and ascites. CMAJ 2006;174:1433-43. [PMID: 16682712 DOI: 10.1503/cmaj.051700] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 126 |
Natarajan SK, Basivireddy J, Ramachandran A, Thomas S, Ramamoorthy P, Pulimood AB, Jacob M, Balasubramanian KA. Renal damage in experimentally-induced cirrhosis in rats: Role of oxygen free radicals. Hepatology 2006;43:1248-56. [PMID: 16729302 DOI: 10.1002/hep.21179] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 127 |
Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm G. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652-60. [PMID: 16697729 DOI: 10.1053/j.gastro.2006.02.010] [Cited by in Crossref: 495] [Cited by in F6Publishing: 516] [Article Influence: 29.1] [Reference Citation Analysis]
|
| 128 |
Cárdenas A, Gines P. Hepatorenal syndrome. Clin Liver Dis 2006;10:371-85, ix-x. [PMID: 16971267 DOI: 10.1016/j.cld.2006.05.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 129 |
Møller S, Bendtsen F, Henriksen JH. Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume. Scand J Gastroenterol 2006;41:451-8. [PMID: 16635914 DOI: 10.1080/00365520500292962] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 130 |
Kalambokis G, Economou M, Kosta P, Papadimitriou K, Tsianos EV. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites. J Clin Gastroenterol 2006;40:342-6. [PMID: 16633107 DOI: 10.1097/01.mcg.0000210101.74618.61] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 131 |
Romanelli RG, Villa GL, Barletta G, Vizzutti F, Lanini F, Arena U, Boddi V, Tarquini R, Pantaleo P, Gentilini P, Laffi G. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: An unblinded randomized trial. World J Gastroenterol 2006; 12(9): 1403-1407 [PMID: 16552809 DOI: 10.3748/wjg.v12.i9.1403] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 102] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 132 |
Vassiliadis T, Garipidou V, Perifanis V, Tziomalos K, Giouleme O, Patsiaoura K, Avramidis M, Nikolaidis N, Vakalopoulou S, Tsitouridis I, Antoniadis A, Semertzidis P, Kioumi A, Premetis E, Eugenidis N. A case of successful management with splenectomy of intractable ascites due to congenital dyserythropoietic anemia type II-induced cirrhosis. World J Gastroenterol 2006; 12(5): 818-821 [PMID: 16521204 DOI: 10.3748/wjg.v12.i5.818] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 133 |
Møller S, Henriksen JH. Cardiopulmonary complications in chronic liver disease. World J Gastroenterol 2006; 12(4): 526-538 [PMID: 16489664 DOI: 10.3748/wjg.v12.i4.526] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 44] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 134 |
Kowdley K. Ascitis. Netter. Gastroenterología 2006. [DOI: 10.1016/b978-84-458-1567-0.50221-6] [Reference Citation Analysis]
|
| 135 |
Kowdley K. Síndrome hepatorrenal. Netter. Gastroenterología 2006. [DOI: 10.1016/b978-84-458-1567-0.50223-x] [Reference Citation Analysis]
|
| 136 |
Kalambokis G, Fotopoulos A, Economou M, Tsianos EV. Octreotide in the treatment of refractory ascites of cirrhosis. Scand J Gastroenterol 2006;41:118-21. [PMID: 16373285 DOI: 10.1080/00365520510024043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 137 |
Terra C, Guevara M, Torre A, Gilabert R, Fernández J, Martín-Llahí M, Baccaro ME, Navasa M, Bru C, Arroyo V, Rodés J, Ginès P. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005;129:1944-53. [PMID: 16344063 DOI: 10.1053/j.gastro.2005.09.024] [Cited by in Crossref: 190] [Cited by in F6Publishing: 195] [Article Influence: 10.6] [Reference Citation Analysis]
|
| 138 |
Albillos A, Bañares R, González M, Catalina MV, Molinero LM. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 2005;43:990-6. [PMID: 16139922 DOI: 10.1016/j.jhep.2005.06.005] [Cited by in Crossref: 124] [Cited by in F6Publishing: 129] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 139 |
Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Christos P, Paraskevi K, Konstantinos P, Katsaraki A, Tsianos EV. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites. Dig Dis Sci 2005;50:1771-7. [PMID: 16187171 DOI: 10.1007/s10620-005-2935-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 140 |
D'Amico G, Luca A, Morabito A, Miraglia R, D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005;129:1282-93. [PMID: 16230081 DOI: 10.1053/j.gastro.2005.07.031] [Cited by in Crossref: 165] [Cited by in F6Publishing: 169] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 141 |
Cardenas A, Ginès P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 2005;42 Suppl:S124-33. [PMID: 15777567 DOI: 10.1016/j.jhep.2004.12.007] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 142 |
Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jiménez W, Arroyo V, Rodés J, Ginès P. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005;41:1282-9. [PMID: 15834937 DOI: 10.1002/hep.20687] [Cited by in Crossref: 267] [Cited by in F6Publishing: 271] [Article Influence: 14.8] [Reference Citation Analysis]
|
| 143 |
Møller S, Bendtsen F, Henriksen JH. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome. Scand J Gastroenterol 2005;40:491-500. [PMID: 16036500 DOI: 10.1080/00365520510012064] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 144 |
Vieira SM, Matte U, Kieling CO, Barth AL, Ferreira CT, Souza AF, Taniguchi A, da Silveira TR. Infected and noninfected ascites in pediatric patients. J Pediatr Gastroenterol Nutr 2005;40:289-94. [PMID: 15735482 DOI: 10.1097/01.mpg.0000154659.54735.1d] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 145 |
Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41:32-9. [PMID: 15690479 DOI: 10.1002/hep.20517] [Cited by in Crossref: 301] [Cited by in F6Publishing: 306] [Article Influence: 16.7] [Reference Citation Analysis]
|
| 146 |
Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-10. [PMID: 15382176 DOI: 10.1002/hep.20405] [Cited by in Crossref: 33] [Cited by in F6Publishing: 112] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 147 |
Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-10. [PMID: 15382176 DOI: 10.1002/hep.20405] [Cited by in Crossref: 376] [Cited by in F6Publishing: 267] [Article Influence: 19.8] [Reference Citation Analysis]
|
| 148 |
Ginès P, Torre A, Terra C, Guevara M. Review article: pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther 2004;20 Suppl 3:57-62; discussion 63-4. [PMID: 15335404 DOI: 10.1111/j.1365-2036.2004.02115.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 149 |
Arroyo V. Review article: hepatorenal syndrome--how to assess response to treatment and nonpharmacological therapy. Aliment Pharmacol Ther 2004;20 Suppl 3:49-54; discussion 55-6. [PMID: 15335402 DOI: 10.1111/j.1365-2036.2004.02114.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 150 |
Cardenas A, Kelleher T, Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004;20:271-9. [PMID: 15274663 DOI: 10.1111/j.1365-2036.2004.02081.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 92] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 151 |
Ginès P, Guevara M, Perez-Villa F. Management of hepatorenal syndrome: another piece of the puzzle. Hepatology 2004;40:16-8. [PMID: 15239080 DOI: 10.1002/hep.20313] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 152 |
Kojima H, Sakurai S, Uemura M, Satoh H, Nakashima T, Minamino N, Kangawa K, Matsuo H, Fukui H. Adrenomedullin contributes to vascular hyporeactivity in cirrhotic rats with ascites via a release of nitric oxide. Scand J Gastroenterol 2004;39:686-93. [PMID: 15370692 DOI: 10.1080/00365520410005306] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 153 |
Cadranel J, Jouannaud V, Duron J. Prise en charge d’un hydrothorax hépatique. Revue des Maladies Respiratoires 2004;21:621-636. [DOI: 10.1016/s0761-8425(04)71372-8] [Reference Citation Analysis]
|
| 154 |
Guevara M, Alessandria C, Uriz J. [Transjugular intrahepatic portosystemic shunt and refractory ascites]. Gastroenterol Hepatol 2004;27:285-91. [PMID: 15056416 DOI: 10.1016/s0210-5705(03)70459-2] [Reference Citation Analysis]
|
| 155 |
Gonzlez Garca M, Ruiz del rbol Olmos L, Albillos Martnez A. Ascitis y s?ndrome hepatorrenal. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 2004;9:504-512. [DOI: 10.1016/s0211-3449(04)70065-x] [Reference Citation Analysis]
|
| 156 |
Restuccia T, Ortega R, Guevara M, Ginès P, Alessandria C, Ozdogan O, Navasa M, Rimola A, Garcia-Valdecasas JC, Arroyo V, Rodés J. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004;40:140-6. [PMID: 14672625 DOI: 10.1016/j.jhep.2003.09.019] [Cited by in Crossref: 170] [Cited by in F6Publishing: 171] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 157 |
Blei AT. Portal hypertensive syndrome: its importance and complications. Portal Hypertension in the 21st Century 2004. [DOI: 10.1007/978-94-007-1042-9_1] [Reference Citation Analysis]
|
| 158 |
González García M, Albillos Martínez A. Terapéutica de las complicaciones de la cirrosis hepática: hemorragia por varices, ascitis y encefalopatía hepática. Medicine - Programa de Formación Médica Continuada Acreditado 2003;8:6444-6454. [DOI: 10.1016/s0304-5412(03)71167-6] [Reference Citation Analysis]
|
